We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Elekta of Sweden has said it would acquire Nasdaq-listed IMPAC Medical for $24
a share in cash, equating to an enterprise value of $190 million, a premium
of 22 percent on the U.S. group's last closing price.
Ciphergen Biosystems announced that the National
Cancer Institute's Early Detection Research Network reported completion of the
first phase of its development of a proteomics platform using Ciphergen's SELDI
ProteinChip System for the detection of prostate cancer.
A common screening test failed to detect potentially cancerous colon growths
95 percent of the time, falsely reassuring patients and doctors, according to
a new study.
Syneron Medical, a maker of medical aesthetic devices using elos (electro-optical
synergy) technology, has announced that American Laser Centers (ALC) purchased
$1.5 million worth of elos aesthetic devices, including the Aurora and Comet
systems.
A 76-year old patient underwent successful aortic heart valve replacement surgery,
becoming the first person in the world to receive the 3F Enable Aortic Heart
Valve, intended to eliminate the need for the cardiac surgeon to suture the
device into the aortic annulus of the patient in the usual manner, saving an
average of 30 minutes or more of cardiopulmonary bypass time.
Terumo has announced payment of damages, in the amount of 590,869 euros, by
Biosphere Medical, in accordance with the judgment rendered in favor of Terumo
Europe Nov. 18, 2004.
Voice Diary has announced it is reviewing its strategic plan and is considering
alternatives to expand its core technology and add additional lines of products
through strategic acquisitions or mergers.
CABG Medical announced that the underwriters of the company's recent initial
public offering of its common stock have exercised in full their over-allotment
option to purchase an additional 825,000 shares of the company's common stock
at a price of $5.50 per share, before deducting underwriting discounts and commissions.